---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-048873"
form_type: "8-K"
ticker: "CRSP"
cik: "0001674416"
company_name: "CRISPR Therapeutics AG"
filed_at: "2026-02-12T23:59:59+00:00"
generated_at: "2026-05-16T03:03:39.140778+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# CRISPR Therapeutics Q4 2025 net loss $130.6M; CASGEVY Q4 revenue $54M, full year $116M

## Summary
- Net loss of $130.6M in Q4 2025 vs $37.3M loss in Q4 2024; collaboration expense increased to $53.7M.
- CASGEVY revenue $54M in Q4, $116M full year 2025; 64 patients infused during the year (30 in Q4).
- Cash, cash equivalents and marketable securities $1,975.8M as of Dec 31, 2025, vs $1,903.8M Dec 31, 2024.
- R&D expenses $83.5M (Q4 2025) vs $71.7M (Q4 2024); G&A $18.4M vs $18.1M.
- Pediatric CASGEVY submissions for ages 5-11 expected H1 2026; in vivo programs CTX460 (mid-2026) and CTX340 (H1 2026) to enter clinic.

## SEC filing metadata
- accession: 0001193125-26-048873
- form_type: 8-K
- ticker: CRSP
- cik: 0001674416
- company_name: CRISPR Therapeutics AG
- filed_at: 2026-02-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048873/0001193125-26-048873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1674416/000119312526048873/crsp-20260212.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-048873
- JSON: https://secwatch.observer/filing/0001193125-26-048873.json
- Plain text: https://secwatch.observer/filing/0001193125-26-048873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.